Smrt zaradi raka na jetrih se je od leta 1990 podvojila

Deli to objavo

In the past two decades, the number of deaths caused by liver cancer has increased by 80%, becoming one of the fastest growing causes of cancer deaths worldwide. According to the “Global Burden of Disease Study”, 830,000 people died of liver cancer in 2016, compared with 464,000 in 1990. This makes liver cancer the second leading cause of cancer death worldwide. The first is pljučni rak. Primary raka na jetrih is the most common liver cancer in the world and can be attributed to heavy drinking and other lifestyle choices, but the most common cause is long-term infection with hepatitis B or hepatitis C virus. These viruses are a major public health challenge, affecting more than 325 million people worldwide. Globally, two thirds of liver cancer deaths are caused by hepatitis B or hepatitis C. The Western Pacific and Southeast Asia are the countries with the largest number of carriers of the virus, and the world ’s highest death rate from liver cancer. In China alone, there were more than 260,000 hepatitis B and C deaths in 2016, accounting for one-third of global liver cancer deaths. In 2016, hepatitis C virus caused 160,000 deaths from liver cancer. The United States ranks first among the top three countries, followed by Japan and China. Hepatitis C does have an effective treatment that can prevent the development of liver cancer. The study also found that hepatitis B virus caused 350,000 deaths from liver cancer, of which China and India accounted for 80%. If people are vaccinated against hepatitis B after birth, the vast majority of these deaths may be prevented. Today, only 52% of countries provide hepatitis B vaccine to newborns. Many people are unaware of the correlation between liver cancer deaths and the dramatic increase in hepatitis B and C viruses. The increase in mortality is ultimately due to low vaccination coverage, lack of routine testing and insufficient access to effective treatment.Raquel Peck, CEO of the World Hepatitis Alliance, said: Before World Cancer Day, we require people to be tested for hepatitis B and C, because this is the first step in prevention. We can stop cancer attacks together. https://medicalxpress.com/news/2018-02-deaths-liver-cancer-1990s-figures.html

Naročite se na naše e-novice

Pridobite posodobitve in nikoli ne zamudite bloga Cancerfax

Več V Razišči

Lutecij Lu 177 dotatat je odobril USFDA za pediatrične bolnike, stare 12 let in več, z GEP-NETS
rak

Lutecij Lu 177 dotatat je odobril USFDA za pediatrične bolnike, stare 12 let in več, z GEP-NETS

Lutetium Lu 177 dotatate, revolucionarno zdravljenje, je nedavno prejelo odobritev ameriške agencije za hrano in zdravila (FDA) za pediatrične bolnike, kar pomeni pomemben mejnik v pediatrični onkologiji. Ta odobritev predstavlja svetilnik upanja za otroke, ki se borijo z nevroendokrinimi tumorji (NET), redko, a zahtevno obliko raka, ki se pogosto izkaže za odpornega na konvencionalne terapije.

Nogapendekin alfa inbakicept-pmln je odobril USFDA za nemišično invazivni rak mehurja, ki se ne odziva na BCG
Rak mehurja

Nogapendekin alfa inbakicept-pmln je odobril USFDA za nemišično invazivni rak mehurja, ki se ne odziva na BCG

»Nogapendekin Alfa Inbakicept-PMLN, nova imunoterapija, je obetavna pri zdravljenju raka na mehurju v kombinaciji s terapijo z BCG. Ta inovativni pristop cilja na specifične označevalce raka, hkrati pa izkorišča odziv imunskega sistema in povečuje učinkovitost tradicionalnih zdravljenj, kot je BCG. Klinična preskušanja razkrivajo spodbudne rezultate, ki kažejo na boljše rezultate pri bolnikih in potencialni napredek pri obvladovanju raka mehurja. Sinergija med Nogapendekinom Alfa Inbakiceptom-PMLN in BCG napoveduje novo dobo pri zdravljenju raka mehurja.«

Rabim pomoč? Naša ekipa vam je pripravljena pomagati.

Želimo vam hitro okrevanje vašega dragega in bližnjega.

Začni klepet
Smo na spletu! Klepetajte z nami!
Skenirajte kodo
Zdravo,

Dobrodošli na CancerFax!

CancerFax je pionirska platforma, namenjena povezovanju posameznikov, ki se soočajo z napredovalim stadijem raka, z revolucionarnimi celičnimi terapijami, kot je CAR T-Cell terapija, TIL terapija in kliničnimi preskušanji po vsem svetu.

Sporočite nam, kaj lahko storimo za vas.

1) Zdravljenje raka v tujini?
2) CAR T-celična terapija
3) Cepivo proti raku
4) Spletno video posvetovanje
5) Protonska terapija